-

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Scientific™ KingFisher™ PlasmidPro prepares high purity plasmid DNA in approximately 75 minutes, half the traditional process time and without the need for centrifugation

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ KingFisher™ PlasmidPro Maxi Processor* (PlasmidPro), the only fully automated maxi-scale plasmid DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi scale purification and delivering high-purity plasmid without manual column preparation and intervention. This is the latest addition to the Thermo Scientific KingFisher instrument portfolio which offers a wide range of plasmid DNA extraction products to help drive efficiency and consistency.

Globally, there are approximately 1,700 clinical trials for cell and gene therapies.1 In recent years, plasmids have been instrumental in the development of cell and gene therapies, monoclonal antibody therapies and mRNA therapies and vaccines. Plasmids are commonly used in a variety of molecular biology applications, including transfection, protein expression, gene therapy, DNA sequencing, and vaccine development. They are a critical laboratory tool that can act as a carrier to deliver desired genes or DNA fragments into target cells.

“With the rapidly growing demand for plasmid DNA purification for emerging therapies, we are proud to accelerate the purification process with a ‘press and go’ solution,” said Amy Butler, president, biosciences, Thermo Fisher Scientific. “By fully automating a critical step in plasmid DNA manufacturing, the PlasmidPro DNA purification system can give time back to our customers to focus on their research and bringing life-saving therapies and vaccines to patients.”

The PlasmidPro purification system requires no set-up, centrifugation or pipetting and completely automates the purification process from culture to plasmid. The product uses a self-contained cartridge pre-filled with all necessary reagents to perform the purification, eliminating the need for additional instrumentation and plastics while minimizing set-up time and contamination risks. Using 100-150 mL of fresh overnight culture, the system is capable of producing up to 1.5 mg DNA yield.

For more information on PlasmidPro, please visit thermofisher.com/plasmidpro.

*For research use only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

1 https://alliancerm.org/wp-content/uploads/2024/05/Trials_Final_Q1_2024.pdf

Contacts

Media Contact Information:
Name: Kristin Blake
Phone: 760-637-1166
E-mail: kristin.blake@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Name: Kristin Blake
Phone: 760-637-1166
E-mail: kristin.blake@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1. Invasive fungal infections are an increasing challenge for healthcare systems w...

Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection. For transplant recipients, finding the right tacrolimus dose as early as possible can be life-changing. If the dose is too low, the body may...

Thermo Fisher Scientific Increases Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40...
Back to Newsroom